Halle Moore, MD

Halle Moore, MD, medical oncologist, the Cleveland Clinic, discusses the use of GnRH agonists to preserve ovarian function and fertility in women with breast cancer.

Moore presented the results of the POEMS study at the 2017 San Antonio Breast Cancer Symposium (SABCS), which demonstrated that when given alongside chemotherapy, goserelin, a gonadotropin-releasing hormone (GnRH) agonist, improved pregnancy outcomes, disease-free survival, and overall survival outcomes in women with early-stage hormone receptor (HR)-negative breast cancer.

GnRH agonists work by putting women into temporary menopause, stopping ovarian cycling and estrogen production. While researchers are currently not entirely sure about why these agents prevent toxicity on the ovaries, one theory, Moore said, is that by preventing ovarian cycling, the ovaries get less blood flow for chemotherapy to impose negative effects—similar to how cooling caps work to prevent chemotherapy-related alopecia.

The POEMS study was also part of a larger meta-analysis, which was also presented at SABCS. This analysis included individual patient data from 5 different studies. Again, results displayed that drugs such as goserelin and other GnRH agonists can improve both pregnancy and survival outcomes, confirming the safety of this class of agents.

Moving forward, Moore mentioned that these findings suggest that physicians should more routinely be offering these agents to young women with breast cancer, especially if they one day hope to have children.

Videos

Dr. Moore Discusses Ovarian Preservation in Breast Cancer

Halle Moore, MD, medical oncologist, Cleveland Clinic, discusses the results of the phase III POEMS study, which was presented at the 2014 ASCO Annual Meeting.

This study looked at whether suppressing ovarian function during adjuvant or neoadjuvant chemotherapy could reduce the risk for long term ovarian failure in premenopausal women with ER-negative breast cancer. Patients were randomized to receive standard cyclophosphamide-containing chemotherapy with or without monthly goserelin.

Results showed a significant reduction (about 70%) in the ovarian failure rate observed in the group treated with goserelin. Further, at 2 years, women who received goserelin had better preserved ovarian function.

There was a higher rate of achieving pregnancy and having successful births among women who received goserelin, Moore says. There was no evidence that goserelin increased the risk of miscarriage, need for elective termination, or other adverse pregnancy events.

Author | Halle Moore, MD

Articles

Dr. Moore Discusses Ovarian Preservation in Breast Cancer

Dr. Halle Moore Discusses Results of the Phase III POEMS Study in Breast Cancer